MNOV | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 2%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.74%

1 Month

-2.07%

3 Months

-14.46%

6 Months

16.39%

1 Year

-5.33%

2 Year

5.97%

Key data

Stock price

$1.42

P/E Ratio

0.00

DAY RANGE

$1.42 - $1.52

EPS

-$0.25

52 WEEK RANGE

$1.17 - $1.96

52 WEEK CHANGE

-$4.70

MARKET CAP

62.289 M

YIELD

N/A

SHARES OUTSTANDING

49.046 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-16-2025

BETA

-1.29

PUBLIC FLOAT

AVERAGE 10 VOLUME

$26,662

AVERAGE 30 VOLUME

$32,189

Company detail

CEO: Yuichi Iwaki
Region: US
Website: medicinova.com
Employees: 10
IPO year: 2006

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

MediciNova, Inc. focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders. MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the. treatment of acute exacerbations of asthma, MN-001 (tipelukast) is an orally bioavailable small molecule compound to treat fibrotic diseases.

MNOV - MEDICINOVA INC